- About
- Advertise
- CureToday.com
- OncLive.com
- OncNursingNews.com
- TargetedOnc.com
- Contact
- Terms and Conditions
- Privacy
- Do Not Sell My Personal Information
© 2022 MJH Life Sciences™ and Cancer Network. All rights reserved.
Deepu Madduri, MD | Authors
Deepu Madduri, MD, on Research in Multiple Myeloma This Past Year
January 22, 2021
The expert in multiple myeloma spoke about the research that she believes will be most influential for patients with multiple myeloma.
Deepu Madduri, MD, on the Future Potential of Therapies to Treat Multiple Myeloma
January 20, 2021
The expert in multiple myeloma highlighted the research which she was most excited to see presented at the ASH Annual Meeting & Exposition.
Deepu Madduri, MD, on Next Steps for the CARTITUDE-1 Trial
January 18, 2021
The phase 1b/2 trial evaluated a single, low-dose infusion of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) in heavily pretreated patients with relapsed or refractory multiple myeloma.
Deepu Madduri, MD, on the Implications of the Phase 1b/2 CARTITUDE-1 Trial Results
January 14, 2021
Based on findings from the trial of ciltacabtagene autoleucel, further investigation of the therapy in other populations of patients with multiple myeloma is already underway.
Deepu Madduri, MD, on the Design of the Phase 1b/2 CARTITUDE-1 Trial
January 12, 2021
The goal of the CARTITUDE-1 study was to evaluate the use of ciltacabtagene autoleucel (cilta-cel; JNJ-68284528) chimeric antigen receptor T-cell therapy in heavily pretreated patients with relapsed or refractory multiple myeloma.
Deepu Madduri, MD, on the Results of the Phase 1b/2 CARTITUDE-1 Trial
January 11, 2021
The study was designed to evaluate the use of ciltacabtagene autoleucel in patients with relapsed or refractory multiple myeloma in the United States.